

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Vincent
Medical**

Vincent Medical Holdings Limited

永勝醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1612)

**VOLUNTARY ANNOUNCEMENT
UNAUDITED REVENUE PERFORMANCE
FOR THE THREE MONTHS ENDED 31 MARCH 2021**

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis with the purpose of allowing the investing public to understand the Group’s revenue performance for the three months ended 31 March 2021 (the “**Period**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that based on the unaudited consolidated management accounts for the Period, the Group’s total revenue reached HK\$181.3 million, representing an increase of 40.3% as compared to the corresponding period in 2020.

The segmental revenue information by product category for the Period is summarised as below:

	For the three months ended 31 March (unaudited)		
	2021	2020	Change
	HK\$ '000	HK\$ '000	
Respiratory products	94,776	72,456	+30.8%
Imaging disposables products	53,969	33,341	+61.9%
Orthopaedic and rehabilitation products	17,577	13,042	+34.8%
Other products	14,971	10,390	+44.1%
Total	181,293	129,229	+40.3%

Growth in respiratory products segment reflected increased demand for respiratory devices and disposables used in the treatment of COVID-19 and other respiratory diseases. During the Period, the Group has deepened its collaboration with a number of partners in expanding both product and market coverage under the respiratory products segment, the Group's management believes that these collaborations will bring sustainable long-term business to the Group despite the uncertainties associated with the course of the COVID-19 pandemic.

Revenue from imaging disposables products and orthopaedic and rehabilitation products segments recorded growth of 61.9% and 34.8%, respectively, this was mainly attributed to new products launch and the recovery of product demand to pre-COVID-19 levels.

The above information was prepared based on the unaudited consolidated management accounts of the Group which have neither been reviewed nor audited by the auditor of the Company and may differ from those in the audited or unaudited financial statements of the Group to be published by the Company on yearly and half-yearly basis due to various uncertainties during the process of collating such sales information.

Shareholders and potential investors of the Company are advised not to place reliance on the aforesaid information and they are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Vincent Medical Holdings Limited
Choi Man Shing
Chairman and Executive Director

Hong Kong, 15 April 2021

As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Mr. Guo Pengcheng as a non-executive Director, and Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.